The purpose of this research study is to see if a drug called LP-118 is safe and effective for treating adults with Philadelphia chromosome-positive (Ph+) B cell acute lymphoblastic leukemia (ALL), when given with ponatinib, dexamethasone, methotrexate and blinatumomab (the standard treatment for this type of cancer).
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Estimation of the Maximum Tolerated Dose (MTD) for LP-118 (Dose Escalation)
Timeframe: The DLT monitoring period is from Day 1 of Course 2 until the end of Course 2 (approximately 21 days).
Identification of the Recommended Phase 2 Dose (RP2D) LP-118 (Dose Expansion)
Timeframe: The DLT monitoring period is from Day 1 of Course 2 until the end of Course 2 (approximately 21 days).